BiotechTube

Sotagliflozin Low Dose + Sotagliflozin High Dose

Phase 3Recruiting
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Type 1 Diabetes (T1D)

Conditions

Type 1 Diabetes (T1D)

Trial Timeline

Jul 1, 2026 → Dec 31, 2030

NCT ID
NCT07211802

About Sotagliflozin Low Dose + Sotagliflozin High Dose

Sotagliflozin Low Dose + Sotagliflozin High Dose is a phase 3 stage product being developed by Lexicon Pharmaceuticals for Type 1 Diabetes (T1D). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07211802. Target conditions include Type 1 Diabetes (T1D).

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT07211802Phase 3Recruiting

Competing Products

20 competing products in Type 1 Diabetes (T1D)

See all competitors
ProductCompanyStageHype Score
add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
77
MKP10241 + PlaceboMankind PharmaPhase 2
52
Daily injection of KBP/placebo for up to 28 daysEli LillyPhase 1
33
LY3209590 + Insulin DegludecEli LillyPhase 1
33
AC2993Eli LillyPhase 3
77
LY3209590 + PlaceboEli LillyPhase 1
33
Insulin Lispro Protamine Suspension + Insulin GlargineEli LillyPhase 3
77
LY2963016 + LantusEli LillyPhase 1
33
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDsEli LillyPre-clinical
23
Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
85
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 3
77
Retatrutide + PlaceboEli LillyPhase 1
33
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePrecigenPhase 1/2
36
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SCEli LillyPhase 1
33
Placebo + LinagliptinEli LillyPhase 3
77
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
85
teplizumab or placeboEli LillyPhase 1
33
LY2428757 + PlaceboEli LillyPhase 2
52
Insulin Efsitora Alfa + Insulin DegludecEli LillyPhase 3
77
LY900014 (SC) + LY900014 (IV)Eli LillyPhase 1
33

Other Products from Lexicon Pharmaceuticals

Sotagliflozin + PlaceboPhase 3
72
Telotristat etiprate + Placebo-matching telotristat etipratePhase 3
72
Telotristat etipratePhase 3
72
Telotristat etiprate + PlaceboPhase 3
72
250 mg LX1033 tablets + Placebo tabletPhase 2
47